Neuracle Genetics Announces Positive Interim Phase 1/2a Data for 바카라 꽁 머니, Showing 91% Reduction in Treatment Burden for Patients with Wet AMD
- Single, low-dose administration of 바카라 꽁 머니 led to a 91% reduction in the annualized anti-VEGF injections in Cohort 1 - A favorable safety profile was observed in Cohort 1, with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) - Vision (BCVA) and retinal thickness (CST) remained stable through 36 weeks, demonstrating durability of treatment effect
[by Ji, Yong Jun] Neuracle Genetics Inc., a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies, announced on September 15 positive interim results from the low-dose cohort of its Phase 1/2a SENSE study of 바카라 꽁 머니. The data, presented on September 12, 2025, at the 58th Annual Scientific Meeting of The Retina Society in Chicago, show that a single subretinal administration of 바카라 꽁 머니 in patients with wet age-related macular degeneration (wet AMD) resulted in a significant reduction in treatment burden and was well-tolerated. The presentation was delivered by Dr. Christopher Riemann of the Cincinnati Eye Institute.
The SENSE study (NCT05984927) is a multicenter, open-label, dose-escalation trial evaluating the safety, tolerability, and preliminary efficacy of 바카라 꽁 머니. The data reported are from the low-dose cohort (1x109 vg/eye; n=6). Analysis showed patients experienced a 91% reduction in the annualized anti-VEGF injections. Prior to the study, these patients required an annual average of 9.8 anti-VEGF injections. Furthermore, Best Corrected Visual Acuity (BCVA) and Central Subfield Thickness (CST) remained stable through 36 weeks of follow-up.
바카라 꽁 머니 continues to be well-tolerated, with no 바카라 꽁 머니-related serious adverse events (SAEs), dose-limiting toxicities (DLTs), or clinically significant retinal pigment epithelium (RPE) changes observed, other than mild or transient adverse events.
“바카라 꽁 머니 was able to dramatically reduce the treatment burden of anti-VEGF injections with a single low-dose administration while maintaining stable vision and anatomical outcomes,” said Dr. Riemann. “With this favorable safety profile, we look forward to seeing the data from the medium- and high-dose cohorts and long-term follow-up.”
Neuracle Genetics highlighted that 바카라 꽁 머니 demonstrated the therapeutic effect at a dose that is a fraction of other investigational AAV gene therapies for wet AMD. A lower effective dose may lead to an improved safety profile and lower treatment costs, potentially strengthening the competitive position of 바카라 꽁 머니.
“We are thrilled that 바카라 꽁 머니 has demonstrated clear efficacy and safety at this low dose,” said Jongmook Kim, CEO of Neuracle Genetics. “We will continue to validate the safety and durability of 바카라 꽁 머니 in the medium- and high-dose cohorts to determine the optimal dose as we prepare to advance into a global Phase 2b trial.”
The company had completed the enrollment of Cohort 2 (3x109 vg/eye; n=6) and is currently evaluating safety and efficacy while actively enrolling Cohort 3 (8x109 vg/eye; n=6).